Search - tctmd.com

Displaying 81 - 100 of 765

Sort: Relevancy | Date

Presentation THT 2025

Emerging Questions in the Face of Multiple Effective Therapies

Presenter: Matthew Maurer

February 11, 2025

Presentation THT 2025

Inotropes, LVADs and Heart Transplant in Amyloid Heart Disease

Presenter: Mazen Hanna

February 11, 2025

Presentation THT 2025

Transcatheter Edge-to-Edge Repair: Buying Time and Function on the Way to Advanced Therapies?

Presenter: Ul Weena

February 11, 2025

Presentation THT 2025

Anti-Amyloid Therapy – Will Depleters Change the Game?

Presenter: Scott Solomon

February 11, 2025

Presentation THT 2025

Silencing TTR With Drugs or CRISPR: Benefits and Risks

Presenter: Ahmad Masri

February 11, 2025

Presentation THT 2025

Novel Therapies for AL Cardiac Amyloidosis – Bi-Specific Antibodies, BCL Inhibitors and More

Presenter: Giada Bianchi

February 11, 2025

Presentation THT 2025

Stabilizers for TTR Amyloidosis: Is One Better Than Another

Presenter: Jan Griffin

February 11, 2025

Presentation THT 2025

Differential Outcome of Hypotension vs. Hypoperfusion in SCAI Stage B Cardiogenic Shock: Insights From Houston Methodist Advanced Heart Failure Registry (HM-AHFR)

Presenter: Sumitabh Singh

February 11, 2025

Presentation THT 2025

Insights Into Hemodynamic Mechanisms of HFpEF From Advanced Invasive Hemodynamic Measurements

Presenter: Philipp Lurz

February 11, 2025

Presentation THT 2025

Preserving Access: Limiting the Use of Advanced Therapies

Presenter: Gerin Stevens

February 11, 2025

Presentation THT 2025

Increasing Access: Reducing Referral Delay in Ambulatory Advanced HF Patients

Presenter: Nir Uriel

February 11, 2025

Presentation Controversies and Advances 2025

MINOCA, ANOCA and INOCA: What’s in a Name!

Presenter: John Beltrame

January 31, 2025

Presentation Controversies and Advances 2025

Changing ABO Blood Type During Ex Vivo Perfusion

Presenter: Fardad Esmailian

January 31, 2025

Presentation Controversies and Advances 2025

The role of double-blind sham-controlled trials in interventional cardiology

Presenter: Rasha Al-Lamee

January 31, 2025

Presentation Controversies and Advances 2025

The Guidelines are Wrong: Everyone with Severe Proximal or Mid Vessel CAD Should Have PCI Regardless of Symptoms

Presenter: Paul S. Teirstein

January 31, 2025

Presentation Controversies and Advances 2025

Antianginals or Stents are Reasonable Alternatives for Patients with Symptomatic CAD

Presenter: Rasha Al-Lamee

January 31, 2025

Presentation Controversies and Advances 2025

Angiography-Derived Coronary Physiology: Even Better than the Real Thing?

Presenter: William F. Fearon

January 31, 2025

Presentation Controversies and Advances 2025

Coronary Plaque: Expanding Role in Guiding Patient Management - Non-Calcified Plaque is the Future

Presenter: Leandro Slipczuk

January 31, 2025

Presentation Controversies and Advances 2025

One Size Does Not Fit All: Only Selected Patients Should Go For AF Ablation

Presenter: Sanjay Dixit

January 31, 2025

Presentation Controversies and Advances 2025

The Good, the Bad and the Ugly of Clinical Trial Design

Presenter: Stuart Pocock

January 31, 2025

Advertisement

Emerging Questions in the Face of Multiple Effective Therapies

Inotropes, LVADs and Heart Transplant in Amyloid Heart Disease

Transcatheter Edge-to-Edge Repair: Buying Time and Function on the Way to Advanced Therapies?

Anti-Amyloid Therapy – Will Depleters Change the Game?

Silencing TTR With Drugs or CRISPR: Benefits and Risks

Novel Therapies for AL Cardiac Amyloidosis – Bi-Specific Antibodies, BCL Inhibitors and More

Stabilizers for TTR Amyloidosis: Is One Better Than Another

Differential Outcome of Hypotension vs. Hypoperfusion in SCAI Stage B Cardiogenic Shock: Insights From Houston Methodist Advanced Heart Failure Registry (HM-AHFR)

Insights Into Hemodynamic Mechanisms of HFpEF From Advanced Invasive Hemodynamic Measurements

Preserving Access: Limiting the Use of Advanced Therapies

Increasing Access: Reducing Referral Delay in Ambulatory Advanced HF Patients

MINOCA, ANOCA and INOCA: What’s in a Name!

Changing ABO Blood Type During Ex Vivo Perfusion

The role of double-blind sham-controlled trials in interventional cardiology

The Guidelines are Wrong: Everyone with Severe Proximal or Mid Vessel CAD Should Have PCI Regardless of Symptoms

Antianginals or Stents are Reasonable Alternatives for Patients with Symptomatic CAD

Angiography-Derived Coronary Physiology: Even Better than the Real Thing?

Coronary Plaque: Expanding Role in Guiding Patient Management - Non-Calcified Plaque is the Future

One Size Does Not Fit All: Only Selected Patients Should Go For AF Ablation

The Good, the Bad and the Ugly of Clinical Trial Design

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content